About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ABBV - AbbVie Inc.| Previous Close | $114.00 | Open | |
| Volume | 2.4K | Market Cap | 202.586B |
| Yield | 4.25 % | Last Dividend | $4.87 |
| Abbvie subsidiary facing patent infringe... | 06/23/21 |
| No summary available. | |
| Jacobio receives $20M from Abbvie to adv... | 06/22/21 |
| Jacobio Pharmaceuticals Group Co. Ltd. has received a milestone payment of $20 million from Abbvie Inc. for dosing the first two patients in the U.S. ... | |
| Cisatracurium Besylate Market Trend, Siz... | 06/22/21 |
| LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, Global Cisatracurium Besylate Market Report, Histo... | |
| Supreme Court declines to hear Abbvie ch... | 06/21/21 |
| No summary available. | |
| Stocks Volume Buzz: IVERIC bio, Inc. (NA... | 06/20/21 |
| IVERIC bio, Inc. (NASDAQ:ISEE) with the stream of -0.17% also noticed, India AbbVie Inc. (NYSE:ABBV) encountered a rapid change of -1.55% in the last ... | |
| Specialty Pharmaceutical Market To See H... | 06/19/21 |
| Stay up to date with Specialty Pharmaceutical Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry g... | |
| AbbVie: Beyond Humira, Framing A Bright ... | 06/18/21 |
| No summary available. | |
| AbbVie Is A Bargain At The Current Price... | 06/18/21 |
| No summary available. | |
| AbbVie declares $1.30 dividend | 06/18/21 |
| No summary available. | |
| Jacobio Announces First Two Patients Dos... | 06/17/21 |
| BEIJING and SHANGHAI and BOSTON , June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been ... | |
| AbbVie: The Investor''s Trifecta | 06/17/21 |
| No summary available. | |
| Global Clinical Trials Review H1, 2021 -... | 06/17/21 |
| DUBLIN--(BUSINESS WIRE)--The "Cerebral Palsy - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com''s of... | |
| AbbVie: A Stellar Dividend Growth Pharma... | 06/17/21 |
| No summary available. | |
| 3 Reasons AbbVie Is A Dividend Champ | 06/17/21 |
| No summary available. | |
| Zhongchao up 5% as it partners AbbVie''s... | 06/16/21 |
| No summary available. | |
| Alvotech Reaches Primary Completion Date... | 06/15/21 |
| REYKJAV??K, Iceland--(BUSINESS WIRE)--Alvotech, today, announced reaching the primary completion date in the switching study for AVT02, the companys p... | |
| Alvotech Reaches Primary Completion Date... | 06/15/21 |
| Alvotech''s Proposed Interchangeable Product for High-Concentration Humira Could Save U.S. Consumers and Taxpayers Billions Annually In May of 2021, A... | |
| SANUWAVEs Valuation Could Surge After Ab... | 06/15/21 |
| No summary available. | |
| UK to open up biosimilar drugs market wi... | 06/15/21 |
| A change in the rules for approval of so-called biosimilar copycat drugs will save the NHS millions and help patients get treated sooner, it was claim... | |
| ABBV Market expectations are for Unifor... | 06/15/21 |
| AbbVie Inc. (ABBV:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 13.3x Uniform P/E. At these levels... | |
| Here is What Hedge Funds Think About Abb... | 06/14/21 |
| No summary available. | |
| AbbVie subsidiary Forest faces more anti... | 06/14/21 |
| AbbVie subsidiary Forest faces more antitrust litigation over Alzheimer''s drug as judge rejects its bid to toss case kdunleavy Mon, 06/14/2021 - 11:4... | |
| Aesthetic Injections Market Trend,Growth... | 06/14/21 |
| LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, Global Aesthetic Injections Market Report, History... | |
| AbbVies ibrutinib, venetoclax combo succ... | 06/13/21 |
| AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VE... | |
| IMBRUVICA?? (ibrutinib) Plus VENCLEXTA??... | 06/12/21 |
| NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and... | |
| IMBRUVICA?? (ibrutinib) Plus VENCLEXTA??... | 06/12/21 |
| NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and... | |
| AbbVie-Roche''s Venclexta Shows Progress... | 06/11/21 |
| Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term | |
| AbbVie, Roche''s Venclexta combo shows s... | 06/11/21 |
| No summary available. | |
| Strong Buy rating | 03/30/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $140.00 to $144.00 | |
| Date | 2021-04-30 (BMO) | Est. (EPS/Rev.) | $2.83/ 12.76B |
| Actual (EPS/Rev.) | / | EPS (TTM) | 5.67 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| OptionIncome | random motion | 95.00 % | Subscribe |
| Option Superstars | James Catzen | 71.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Biotech Fund | Scientia Equity Research | 63.00 % | Subscribe |
| Rocket Investing | Waqas | 59.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
